Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03693-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Leiah J Brigitha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Belgian Federal Public Service of Health, Vlaamse Liga Tegen Kanker.
Abstract (Originalsprache)
BACKGROUND: PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population. METHODS: Infants with ALL who received treatment with PEGasparaginase were included in our population pharmacokinetic assessment employing non-linear mixed effects modelling (NONMEM). RESULTS: 68 infants with ALL, with a total of 388 asparaginase activity samples, were included. PEGasparaginase doses ranging from 400 to 3,663 IU/m2 were administered either intravenously or intramuscularly. A one-compartment model with time-dependent clearance, modeled using a transit model, provided the best fit to the data. Body weight was significantly correlated with clearance and volume of distribution. The final model estimated a half-life of 11.7 days just after administration, which decreased to 1.8 days 14 days after administration. Clearance was 19.5% lower during the post-induction treatment phase compared to induction. CONCLUSION: The pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1-18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m2 for infants without dose adaptations according to age, and implementing therapeutic drug monitoring as standard practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
- Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
- Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, USA.
- Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark.
- Department of Pediatrics, Medical University of Lodz, Oncology & Hematology, 91-738, Lodz, Poland.
Förderung
- Belgian Federal Public Service of Health
- Vlaamse Liga Tegen Kanker
Zitieren
APA
Brigitha, L. J., Mondelaers, V., Liu, Y., Albertsen, B. K., Zalewska-Szewczyk, B., Rizzari, C., Kotecha, R. S., Pieters, R., Huitema, A. D. R., & van der Sluis, I. M. (2024). Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03693-3
Vancouver
Brigitha LJ, Mondelaers V, Liu Y, Albertsen BK, Zalewska-Szewczyk B, Rizzari C, et al. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03693-3
BibTeX
@article{Brigitha2024,
author = {Brigitha, Leiah J and Mondelaers, Veerle and Liu, Yiwei and Albertsen, Birgitte K and Zalewska-Szewczyk, Beata and Rizzari, Carmelo and Kotecha, Rishi S and Pieters, Rob and Huitema, Alwin D R and van der Sluis, Inge M},
title = {Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03693-3}
}
EUVIMED